New findings out of Emory University are challenging existing theories about the origins of Alzheimer's, the leading cause of dementia in the elderly worldwide. A team led by researchers at the Goizueta Brain Health Institute ...
Aug 12, 2024
0
189
Memory loss, confusion, speech problems—Alzheimer's disease is the most common cause of dementia, affecting about 35 million people worldwide, and the number is growing.
Aug 9, 2024
0
83
A University of Kansas study of rare gene mutations that cause hereditary Alzheimer's disease shows these mutations disrupt the production of a small sticky protein called amyloid.
Feb 29, 2024
0
67
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body temperatures.
Feb 21, 2024
0
68
The effects of Alzheimer's disease are devastating: not being able to recognize loved ones, losing precious memories, losing the ability to perform simple tasks, suffering through mood swings, and so on. Not only are memory ...
Jan 18, 2024
0
49
Despite affecting millions worldwide, Alzheimer's disease (AD) has long lacked effective treatments due to a fundamental inadequacy of our understanding of its etiology and pathogenesis. The absence of an integrative theory ...
Dec 18, 2023
0
40
A new USC Leonard Davis School of Gerontology study challenges existing ideas of how buildup of a protein called amyloid beta (Aβ) in the brain is related to Alzheimer's disease.
Jan 6, 2023
0
540
When Emily Largent worked as an ICU nurse at UCLA, she didn't shy away from the difficult cases. It wasn't necessarily the medical procedures themselves that were challenging; caring for patients after organ transplants or ...
Dec 5, 2022
0
43
The overexpression of a gene tied to cell division and the structure and function of neurons may prevent and protect against cognitive decline in both mice and humans with Alzheimer's disease (AD), according to a new study ...
Oct 25, 2022
0
95
Partner companies Eisai and Biogen recently announced promising clinical trial results for their new Alzheimer's drug lecanemab. Over 18 months, patients treated with lecanemab experienced slower symptom progression than ...
Oct 14, 2022
0
105
